Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Experimental ADC Micvotabart Pelidotin Shows Promise in Head and Neck Cancers

1 day ago 1

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

An experimental antibody-drug conjugate called micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase 1 clinical trial of heavily pretreated patients with head and neck cancers. The findings were presented on November 19, 2026, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics by principal investigator Faye Johnson, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center. The investigational agent, developed by Pyxis Oncology, currently holds U.S. Food and Drug Administration Fast Track Designation for this therapeutic setting.

The study specifically evaluated the effectiveness of MICVO in 33 efficacy-evaluable patients with recurrent or metastatic head and neck squamous cell carcinoma who had previously progressed after undergoing prior therapies. This patient population faces significant clinical challenges, as historical response rates to standard-of-care treatments in this setting are approximately 15 percent, with progression typically occurring in less than two months. This condition affects about 20,000 individuals annually in the United States, representing a substantial unmet medical need with limited treatment options currently available for those whose disease advances after initial therapy.

Among the 33 evaluable participants, MICVO achieved a confirmed overall response rate of 39 percent, which included one documented complete response. The trial also demonstrated a median progression-free survival of 6.7 months. Survival analysis further indicated an 81 percent one-year overall survival rate. According to the research team, positive therapeutic responses were observed across participants regardless of their human papillomavirus status or their specific prior treatment history. The Phase 1 trial enrolled a total of 36 patients, 33 of whom were able to be evaluated for treatment efficacy.

Micvotabart pelidotin functions through a targeted delivery mechanism designed to exploit the tumor microenvironment. The antibody component of the conjugate is engineered to bind specifically to the extradomain-B of fibronectin, a target found in high levels within the extracellular matrix surrounding tumor cells but which is uncommon in normal, healthy tissue. This targeting allows the antibody-drug conjugate to concentrate directly at the tumor site, where it releases its therapeutic payload. The payload carried by MICVO is auristatin-0101, a chemotherapy-type drug that works by disrupting the cell division process, thereby killing the cancer cells.

The trial’s safety assessment found that adverse effects were consistent with the previously recorded toxicity profiles of auristatin-based therapies. Approximately half of the patients experienced at least one treatment-related grade 3 adverse effect, though most events were described as manageable and reversible. Adverse effects occurring in more than 10 percent of participants included fatigue, nerve damage in the hands and feet, joint pain, nausea, rash, and changes in red blood cell counts. More serious nerve damage occurred in six patients at a median of five and a half months of treatment; however, symptoms improved in all six cases following dose adjustments, with five patients improving to asymptomatic, minimally symptomatic, or better status.

Based on these initial findings, further clinical development is underway. A Phase 3 trial is scheduled to begin in 2027 to evaluate MICVO as a monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma who have received at least one prior systemic treatment. Additionally, a Phase 2 trial is currently testing the efficacy of the agent when administered in combination with pembrolizumab. The research was funded by Pyxis Oncology, and a complete list of author disclosures is available with the meeting abstract.

Subject of Research: Phase 1 clinical evaluation of the antibody-drug conjugate micvotabart pelidotin for recurrent or metastatic head and neck squamous cell carcinoma

Article Title: Experimental ADC shows promising initial activity in head and neck cancers

Article References: Experimental ADC shows promising initial activity in head and neck cancers. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: micvotabart pelidotin, MICVO, PYX-201, antibody-drug conjugate, head and neck cancer, head and neck squamous cell carcinoma, Phase 1 clinical trial, Pyxis Oncology, MD Anderson Cancer Center, Faye Johnson, extradomain-B of fibronectin, auristatin-0101, progression-free survival, overall response rate, overall survival, EORTC-NCI-AACR Symposium, Fast Track designation, targeted oncology

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway